MLBON.PA Bonyf NV

Healthcare Health Care Equipment & Supplies Euronext Paris
1.90 EUR
Close of Oct 14, 2026
1.80 12.90
Market cap
EUR 1.12M
P/E
-
P/B
17.90x
ROE
-1.4%
Dividend yield
-
Fundamental score
0.8/5

Ratios use the latest price and the fiscal year ending Dec 2024.

Is MLBON.PA undervalued?

Graham number

The Graham number of Bonyf NV cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bonyf NV fundamental analysis

2 of 11 checks passed

ROE 0/2

Negative ROE (-22.44%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-5.39%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

DER 1/2

The stock maintains a fair debt to equity ratio (96%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

Assets Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Graham Number 0/1

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Buffet Intrinsic Value 0/1

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Bonyf NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bonyf NV

bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally. The company offers PerioTabs, a brushing solution for gums, teeth, and dental implants to help reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis; and AphtoFix, a film-forming cream for the local treatment of mouth ulcers. It also provides denture care products, such as OlivaFix denture adhesive creams and NitrAdine dis…

Full company profile